GlaxoSmithKline

GSK aims to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world. Every hour we spend more than £300,000 (US$562,000) in our search for new medicines that can make a difference to patients. We are one of the pharmaceutical industry leaders, with an estimated 7% of the world's pharmaceutical market and one of the few companies researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria. As a company with a firm foundation in science, we have a flair for research and a track record of turning that research into powerful, marketable drugs.

Why GlaxoSmithKline is supporting the Big Innovation Centre

"Discovering and making transformative therapies for patients is the heart of GlaxoSmithKline’s business.

We are in the midst of one of the most exciting periods of scientific and technical advance, where repair and regeneration of tissues, and prevention and cure of many diseases, is on the horizon.

However, to take that vast scientific potential and translate it into real-life health care is challenging to deliver. At times we may not be looking in the right places for solutions that could be sitting in another area of bioscience or even in another sector.

The inspiration and creativity that evolves from opening up knowledge transfer and innovation is expected to make a critical difference to success in our industry. GSK therefore supports the Big Innovation Centre’s goal of building an environment in which the UK can flourish and become a global innovation hub and is excited to be working with the Big Innovation Centre and its partners to help make this happen."

Click here to access the GlaxoSmithKline site >